Rocket Pharma announces dosing has commenced in phase 1 clinical trial of RP-A501
Rocket Pharmaceuticals announces that patient dosing has commenced in the open-label, Phase 1 clinical trial of RP-A501, the Company’s adeno-associated viral vector-based gene therapy for treatment of Danon disease. UCSD Health is the initial and lead center for the Phase 1 clinical trial. June 18, 2019